Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the liraglutide and semaglutide market grown over the years?

Recent years have seen the market size for liraglutide and semaglutide expand significantly. The market, projected to rise from $15.19 billion in 2024 to $16.98 billion in 2025, is expected to experience a compound annual growth rate (CAGR) of 11.8%. The historical growth in this market can be credited to factors such as an increased depiction of diabetes, a rising occurrence of diseases related to obesity, an increase in clinical trials, heightened investment in research and development related to diabetes, and a growing need for convenient treatment options.

What Is the forecasted market size and growth rate for the liraglutide and semaglutide market?

In the coming years, the market for liraglutide and semaglutide is expected to experience an accelerated expansion. By 2029, this market will be worth an estimated $26.24 billion, with a compound annual growth rate (CAGR) of 11.5%. The predicted rise in the forecast period can be linked to the growing popularity of GLP-1 receptor agonists, increased spending on healthcare, wider product offerings from pharmaceutical firms, escalating disposable incomes, and a rising elderly population at risk of diabetes. Notable trends within the forecast period include the confluence of digital health platforms, the execution of tailored dosing plans, strides in drug delivery technology, the creation of biosimilar models, and the introduction of artificial intelligence in making treatment decisions.

Get your liraglutide and semaglutide market report here!

https://www.thebusinessresearchcompany.com/report/liraglutide-and-semaglutide-global-market-report

What are the major factors driving growth in the liraglutide and semaglutide market?

The growth of the liraglutide and semaglutide markets is expected to be boosted by an increasing number of diabetic patients. Diabetes, a chronic disease characterized by increased blood sugar levels due to insulin resistance or inadequate insulin production, is primarily associated with sedentary lifestyles, poor eating habits, and genetic factors. Liraglutide and semaglutide play a crucial role in diabetes treatment by effectively controlling blood glucose levels and reducing the risk of diabetes-related complications. To illustrate, the National Health Service, a UK government department, reported in June 2024 that in 2023, the NHS discovered an additional 549,000 individuals in England who were at risk of type 2 diabetes. This brought the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, which is a significant increase from 3,065,825 in 2022 – a nearly 20% rise. Consequently, the increase in the number of diabetic patients is driving the growth of the liraglutide and semaglutide markets.

What key areas define the segmentation of the global liraglutide and semaglutide Market?

The liraglutide and semaglutide market covered in this report is segmented –

1) By Type: Pills, Liquid

2) By Administration: Parenteral, Oral

3) By Application: Type 2 Diabetes Mellitus, Obesity, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Pills: Oral Tablets (Liraglutide, Semaglutide), Extended-Release Oral Formulations

2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide), Pre-Filled Syringes, Vials For Injection

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18400&type=smp

What are the top market players propelling the growth of the liraglutide and semaglutide industry?

Major companies operating in the liraglutide and semaglutide market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Pharma Co. Ltd., Shionogi & Co. Ltd., Cadila Pharmaceuticals, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Biocon, Glenmark Pharmaceuticals Ltd., Bachem, Zealand Pharma, Shenzhen JYMed Technology Co. Ltd., Incepta Pharmaceuticals Ltd.

What key trends are currently impacting the liraglutide and semaglutide market’s development?

Significant players in the liraglutide and semaglutide markets, such as Glenmark Pharmaceuticals Ltd., are creating biosimilar drugs for diabetes to intensify the control of glucose levels and decrease cardiovascular hazards in people with diabetes. These anti-diabetic biosimilars, cost-effective, near-exact replicas of original diabetes biologics, promise the same health advantages as the original medication. In January 2024, Glenmark Pharmaceuticals Ltd., a pharmaceutical enterprise based in India, introduced a Liraglutide biosimilar for the first time in the country. This anti-diabetic drug biosimilar, designed to better glycemic control in adults suffering from type 2 diabetes mellitus, has significantly extended nationwide accessibility by cutting daily therapy expenses. This Liraglutide biosimilar, costing around INR 100 for a daily dosage of 1.2 mg, brings down the cost of therapy by roughly 70% and demands a prescription for acquisition.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18400

What regions are dominating the liraglutide and semaglutide market growth?

North America was the largest region in the liraglutide and semaglutide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Glufosinate Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/glufosinate-global-market-report

Self-Monitoring Blood Glucose (SMBG) Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/self-monitoring-blood-glucose-smbg-devices-global-market-report

Glutamic Acid Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/glutamic-acid-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: